Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | CASR | P41180 | 5/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29361985 | 0.81 | SMN1; SMN2 (0.49) | SLC6A4SLC6A2HTR2AHRH1HTR2B | |
| SCHEMBL29508554 | 0.79 | CASR (0.58) | SLC6A4SLC6A2SLC6A3ADRB1KCNH2 | |
| SCHEMBL10278340 | 0.77 | SLC6A2 (0.40) | SLC6A4SLC6A2HTR2AHRH1HTR2B | |
| SCHEMBL29508557 | 0.74 | CASR (0.53) | LMNAALDH1A1CASRCYP3A4CYP1A2 | |
| SCHEMBL12802344 | 0.72 | L3MBTL1 (0.58) | SLC6A4SLC6A2HTR2AHRH1HTR2B | |
| SCHEMBL13518462 | 0.71 | MAPT (0.51) | L3MBTL1LMNAALDH1A1MAPTCYP3A4 | |
| SCHEMBL2554590 | 0.71 | SLC6A4 (0.57) | SLC6A4SLC6A2HTR2AHRH1HTR2B | |
| Chlorobenzene SCHEMBL4687874 | 0.70 | NPSR1 (0.44) | ADRB1LMNAALDH1A1ADRB2CYP2D6 | |
| SCHEMBL5873468 | 0.70 | SLC6A4 (0.61) | SLC6A4SLC6A2HTR2AHRH1HTR2B | |
| SCHEMBL28848601 | 0.69 | SLC6A4 (0.67) | SLC6A4SLC6A2HTR2AHRH1HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3366306-A2 | USE OF SOME PEPTIDES IN DIAGNOSIS AND TREATMENT OF DIABETES, OBESITY AND METABOLIC DISEASES ASSOCIATED THERETO | Istanbul Universitesi Rektorlugu (TR) | 2018-08-29 | — | — | EP | claimed |
| EP-3351262-A1 | CURAGLUTIDE FOR IN TREATMENT OF PREDIABETES, DIABETES, OBESITY AND METABOLIC DISEASES ASSOCIATED THERETO | Istanbul Universitesi Rektorlugu (TR) | 2018-07-25 | — | — | EP | claimed |
| WO-2026107229-A1 | REDUCING THE ADDICTIVE LIABILITY OF OPIOID ANALGESICS BY CO- ADMINISTERING 5HT2 RECEPTOR AGONISTS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20230035892-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | FLAGSHIP PIONEERING, INC. | 2023-02-02 | — | — | US | disclosed |
| US-11274158-B2 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| US-20220033490-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING CHRNA6 INHIBITORS | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2022-02-03 | — | — | US | disclosed |
| US-11208475-B1 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using serotonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210283217-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-09-16 | — | — | US | disclosed |
| US-11059886-B1 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using GRM8 activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20210177823-A1 | NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF CANCER | FLAGSHIP PIONEERING INNOVATIONS V, INC. | 2021-06-17 | — | — | US | disclosed |
| US-11034751-B1 | Methods and compositions for treating cancer using serotonin receptor inhibitors | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20040058896-A1 | Pharmaceutical preparation comprising an active dispersed on a matrix | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | US | disclosed |
| US-6680047-B2 | FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2004-01-20 | — | — | US | disclosed |
| EP-1341527-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA Pharma AG (DE) | 2003-09-10 | — | — | EP | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| WO-2002045693-A1 | PHARMACEUTICAL PREPARATION COMPRISING AN ACTIVE DISPERSED ON A MATRIX | ALTANA PHARMA AG (DE) | 2002-06-13 | — | — | WO | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220033490-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING CHRNA6 INHIBITORS | CHRNA6, CHRNA1, CHRNB1 | SLC6A4 510/4885SLC6A2 189/4885HTR2A 857/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | SLC6A4 2995/4885SLC6A2 2713/4885HTR2A 3941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.